PL3346995T3 - Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności - Google Patents

Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności

Info

Publication number
PL3346995T3
PL3346995T3 PL16798063T PL16798063T PL3346995T3 PL 3346995 T3 PL3346995 T3 PL 3346995T3 PL 16798063 T PL16798063 T PL 16798063T PL 16798063 T PL16798063 T PL 16798063T PL 3346995 T3 PL3346995 T3 PL 3346995T3
Authority
PL
Poland
Prior art keywords
treatment
immunodeficiency virus
human immunodeficiency
therapeutic compositions
therapeutic
Prior art date
Application number
PL16798063T
Other languages
English (en)
Inventor
Lei Hong
Benjamin Micah Collman
Joanna M. Koziara
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57346085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3346995(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3346995T3 publication Critical patent/PL3346995T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16798063T 2015-11-09 2016-11-08 Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności PL3346995T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562253042P 2015-11-09 2015-11-09
US201662399999P 2016-09-26 2016-09-26
EP16798063.0A EP3346995B1 (en) 2015-11-09 2016-11-08 Therapeutic compositions for treatment of human immunodeficiency virus
PCT/US2016/060989 WO2017083304A1 (en) 2015-11-09 2016-11-08 Therapeutic compositions for treatment of human immunodeficiency virus

Publications (1)

Publication Number Publication Date
PL3346995T3 true PL3346995T3 (pl) 2020-03-31

Family

ID=57346085

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16798063T PL3346995T3 (pl) 2015-11-09 2016-11-08 Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności

Country Status (27)

Country Link
US (4) US10548846B2 (pl)
EP (2) EP3346995B1 (pl)
JP (1) JP6621933B2 (pl)
KR (4) KR20240095320A (pl)
CN (2) CN108348473B (pl)
AU (2) AU2016354007C9 (pl)
BR (1) BR102016026127A2 (pl)
CA (1) CA2948021C (pl)
CL (1) CL2018001199A1 (pl)
CO (1) CO2018004776A2 (pl)
CR (1) CR20180253A (pl)
EA (1) EA201890654A1 (pl)
EC (1) ECSP18033723A (pl)
ES (1) ES2757560T3 (pl)
IL (1) IL258459A (pl)
MX (1) MX2018005729A (pl)
NZ (1) NZ741957A (pl)
PE (1) PE20181207A1 (pl)
PH (1) PH12018501001A1 (pl)
PL (1) PL3346995T3 (pl)
PT (1) PT3346995T (pl)
SG (1) SG11201802983TA (pl)
SI (1) SI3346995T1 (pl)
SV (1) SV2018005682A (pl)
TW (2) TW202220660A (pl)
UY (1) UY36981A (pl)
WO (1) WO2017083304A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (pl) 2014-06-20 2018-06-23
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US20200171039A1 (en) * 2017-08-09 2020-06-04 Viiv Healthcare Company Combinations and uses and treatments
JP2020529461A (ja) * 2017-08-09 2020-10-08 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及び治療
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
JP7313438B2 (ja) * 2018-09-19 2023-07-24 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの予防のためのインテグラーゼ阻害剤
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
EP3653629A1 (en) * 2018-11-16 2020-05-20 Sandoz AG Acid addition salts of an integrase strand transfer inhibitor
CN111686082A (zh) * 2019-03-11 2020-09-22 苏州特瑞药业有限公司 一种富马酸磷丙替诺福韦制剂及其制备方法
CN119174736A (zh) * 2024-09-09 2024-12-24 安徽贝克生物制药有限公司 一种三联复方片及制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331208A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人肿瘤坏死因子受体21.45和编码这种多肽的多核苷酸
OA12393A (en) 2000-07-21 2006-04-18 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
SI1583542T1 (sl) 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
DK1874117T3 (da) 2005-04-28 2013-09-23 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AP2702A (en) 2005-12-30 2013-07-23 Gilead Sciences Inc Methods for improving the pharmacokinetics of HIV integrase inhibitors
WO2008043829A2 (en) 2006-10-14 2008-04-17 Boehringer Ingelheim International Gmbh Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine
SG173544A1 (en) 2009-02-06 2011-09-29 Gilead Sciences Inc Tablets for combination therapy
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
SMT201700574T1 (it) 2011-07-07 2018-01-11 Gilead Sciences Inc Formulazioni delle combinazioni di darunavir
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
MD20140091A2 (ro) 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (pl) * 2013-07-12 2018-07-21
JP2016528240A (ja) * 2013-08-14 2016-09-15 ラシオファルム ゲーエムベーハー ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (pl) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EA201792592A1 (ru) 2015-06-30 2018-06-29 Джилид Сайэнс, Инк. Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
PE20181207A1 (es) * 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
KR102100436B1 (ko) 2018-10-30 2020-04-13 울산과학기술원 강자성 원소 치환형 상온 다강성 물질 및 그 제조 방법

Also Published As

Publication number Publication date
TW202220660A (zh) 2022-06-01
ES2757560T3 (es) 2020-04-29
WO2017083304A8 (en) 2018-04-19
TW201726139A (zh) 2017-08-01
AU2016354007C9 (en) 2020-10-01
PE20181207A1 (es) 2018-07-23
KR20200106222A (ko) 2020-09-11
CA2948021A1 (en) 2017-05-09
AU2020200995A1 (en) 2020-02-27
AU2016354007A8 (en) 2018-06-14
US11744802B2 (en) 2023-09-05
EP3632415A1 (en) 2020-04-08
EP3346995A1 (en) 2018-07-18
HK1256093A1 (zh) 2019-09-13
HK1256903A1 (en) 2019-10-04
CR20180253A (es) 2018-07-16
US10548846B2 (en) 2020-02-04
MX2018005729A (es) 2018-08-09
KR20180067702A (ko) 2018-06-20
EP3346995B1 (en) 2019-08-28
CL2018001199A1 (es) 2018-09-28
EA201890654A1 (ru) 2018-10-31
KR102153996B1 (ko) 2020-09-09
CN108348473B (zh) 2021-06-18
CN113546052A (zh) 2021-10-26
CO2018004776A2 (es) 2018-06-20
BR102016026127A2 (pt) 2017-05-16
CN108348473A (zh) 2018-07-31
AU2016354007A1 (en) 2018-05-10
AU2016354007C1 (en) 2020-09-10
TWI737647B (zh) 2021-09-01
KR20230015512A (ko) 2023-01-31
NZ741957A (en) 2019-04-26
AU2020200995B9 (en) 2022-04-28
SV2018005682A (es) 2018-08-15
ECSP18033723A (es) 2018-05-31
AU2016354007B2 (en) 2019-11-14
IL258459A (en) 2018-05-31
US20260027061A1 (en) 2026-01-29
KR20240095320A (ko) 2024-06-25
CA2948021C (en) 2024-06-18
PT3346995T (pt) 2019-11-22
SG11201802983TA (en) 2018-05-30
AU2020200995B2 (en) 2022-04-07
JP2018532811A (ja) 2018-11-08
SI3346995T1 (sl) 2019-11-29
US20220378798A1 (en) 2022-12-01
UY36981A (es) 2017-06-30
PH12018501001A1 (en) 2018-12-17
US20210052502A1 (en) 2021-02-25
US20170189337A1 (en) 2017-07-06
WO2017083304A1 (en) 2017-05-18
JP6621933B2 (ja) 2019-12-18
KR102606625B1 (ko) 2023-11-27

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
PL3346995T3 (pl) Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
HUE045137T2 (hu) HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3173092T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
HUE059694T2 (hu) Készítmény rák kezelésére
DK3360508T3 (da) Hjælpeanordning til dental behandling
DK3068392T5 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
PT3286166T (pt) Inibidores de replicação do vírus da imunodeficiência humana
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
HUE049413T2 (hu) Nazális porkészítmény hipoglikémia kezelésére
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
HUE048924T2 (hu) Csont morfogenetikus fehérjék terápiás alkalmazása
IL257355B (en) Selection of patients for combination therapy
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases